Intellia Therapeutics Stock Performance
| NTLA Stock | USD 14.30 0.50 3.62% |
The company retains a Market Volatility (i.e., Beta) of 2.88, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Intellia Therapeutics will likely underperform. At this point, Intellia Therapeutics has a negative expected return of -0.64%. Please make sure to check out Intellia Therapeutics' daily balance of power, and the relationship between the skewness and day typical price , to decide if Intellia Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Intellia Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's essential indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 3.62 | Five Day Return (1.38) | Year To Date Return (53.60) | Ten Year Return (35.29) | All Time Return (35.29) |
1 | Top three trends in precision medicine | 09/19/2024 |
2 | Disposition of 2012 shares by Dube Michael P of Intellia Therapeutics at 19.01 subject to Rule 16b-3 | 10/02/2024 |
3 | 2 Cathie Wood Stocks That Could Soar 32 percent and 282, According to Wall Street | 10/09/2024 |
4 | Intellia Therapeutics Inc earnings beat by 0.05, revenue topped estimates | 11/07/2024 |
5 | Intellia Therapeutics Releases Earnings Results, Beats Expectations By 0.03 EPS | 11/08/2024 |
6 | Intellia Therapeutics Given New 55.00 Price Target at Barclays | 11/11/2024 |
7 | Intellia Therapeutics Hits New 1-Year Low Time to Sell | 11/15/2024 |
8 | CF Foundation Invests Up to 15 million in ReCode Therapeutics to Develop a Gene Editing Therapy | 11/18/2024 |
9 | Intellia Therapeutics Given New 70.00 Price Target at Wells Fargo Company | 11/19/2024 |
10 | Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies SNS Insider | 11/22/2024 |
| Begin Period Cash Flow | 535.5 M |
Intellia |
Intellia Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,294 in Intellia Therapeutics on August 27, 2024 and sell it today you would lose (864.00) from holding Intellia Therapeutics or give up 37.66% of portfolio value over 90 days. Intellia Therapeutics is currently does not generate positive expected returns and assumes 4.3707% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Intellia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intellia Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intellia Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intellia Therapeutics, and traders can use it to determine the average amount a Intellia Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1456
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NTLA |
Estimated Market Risk
| 4.37 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.64 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Intellia Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intellia Therapeutics by adding Intellia Therapeutics to a well-diversified portfolio.
Intellia Therapeutics Fundamentals Growth
Intellia Stock prices reflect investors' perceptions of the future prospects and financial health of Intellia Therapeutics, and Intellia Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intellia Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (15.89) % | ||||
| Current Valuation | 899.94 M | ||||
| Shares Outstanding | 101.85 M | ||||
| Price To Earning | (19.91) X | ||||
| Price To Book | 1.51 X | ||||
| Price To Sales | 33.80 X | ||||
| Revenue | 36.27 M | ||||
| Gross Profit | (367.86 M) | ||||
| EBITDA | (506.31 M) | ||||
| Net Income | (481.19 M) | ||||
| Cash And Equivalents | 874.28 M | ||||
| Cash Per Share | 11.50 X | ||||
| Total Debt | 115.35 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 7.24 X | ||||
| Book Value Per Share | 9.46 X | ||||
| Cash Flow From Operations | (394.09 M) | ||||
| Earnings Per Share | (5.45) X | ||||
| Market Capitalization | 1.46 B | ||||
| Total Asset | 1.3 B | ||||
| Retained Earnings | (1.66 B) | ||||
| Working Capital | 883.12 M | ||||
| Current Asset | 77.63 M | ||||
| Current Liabilities | 10.7 M | ||||
About Intellia Therapeutics Performance
By analyzing Intellia Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Intellia Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Intellia Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Intellia Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3.8 K | -4 K | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.43) | (0.46) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.46) | (0.48) |
Things to note about Intellia Therapeutics performance evaluation
Checking the ongoing alerts about Intellia Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intellia Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intellia Therapeutics generated a negative expected return over the last 90 days | |
| Intellia Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 36.27 M. Net Loss for the year was (481.19 M) with loss before overhead, payroll, taxes, and interest of (367.86 M). | |
| Intellia Therapeutics currently holds about 874.28 M in cash with (394.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.5. | |
| Intellia Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies SNS Insider |
- Analyzing Intellia Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intellia Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Intellia Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intellia Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intellia Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intellia Therapeutics' stock. These opinions can provide insight into Intellia Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |